/biz/ - Business & Finance

AU(ph) is GOLD Edition

>Brokers
https://pastebin.com/F1yujtVq (embed)

>Stock market words:
https://pastebin.com/VtnpN5iJ (embed)

>Risk management:
https://pastebin.com/sqJUcbjp (embed)

>Live Bloomberg stream:
http://www.livenewson.com/american/bloomberg-television-business.html

>Educational sites:
https://www.investopedia.com/
https://www.khanacademy.org/economics-finance-domain

>Free chart:
https://www.tradingview.com
https://www.finscreener.com/

>Screeners:
https://finviz.com/
https://www.tradingview.com/screener
https://e-hentai.org/g/1759272/c1c4b2d923/
https://etfdb.com/

>Pre-Market Data and Live data:
https://www.investing.com/indices/indices-futures
https://finance.yahoo.com/

>Bio-pharma Catalyst Calendar:
https://biopharmcatalyst.com

>I love Lum

>Boomer Investing 101:
https://www.bogleheads.org/wiki/Getting_started

>Dividend Reinvestment (DRIP) calculator:
https://www.dividendchannel.com/drip-returns-calculator/

>List of hedge fund holdings:
https://fintel.io/

>Misc:
https://squeezemetrics.com/monitor
https://market24hclock.com/
https://tradingeconomics.com

Previous: >>26507616

>>26393299
Alright lads, that's all from me for the day.
Enjoy the weekend, relax.
We won.

AUPH is gold.

>>26379651
You are buying AUPH now. And holding it.

>>26379225
We will make it, brother.

LAST CALL

Take the AUPH pill.

PDUFA deadline is TODAY(most expect it to be today AH).

If approved, it will be the best lupus nephritis drug on the market. The only other one is made by GIK, but:
>Oral pill vs IV
>More effective
Who will take IV's for a year, in the corona-climate, when you can just take a nice little pill?

The company has $400m in cash right now, with more than $50m more from their partner (Otsuka) on approval.

Drug has been fast-tracked due to the incredibly good P2 results (p<0.001)

lupus.org estimates up to 1.5 million people with lupus. PG says 400K. 70% of that 400K will be of the SLE form of lupus or 280K. Of those 280K, 40%(PG) or 112K will get LN.

Let's assume a modest market penetration of 15% = 17k patients. With a yearly treatment cost of 70k, we are looking at a (very conservative) 1.2B in revenue per year. This is only in the US.

We are sitting on a 1.91B market cap and 126M shares out. The ratios are incredible.

AUPH has 2027 patent of composition guaranteed for their drug, which means 6 full years of profits. However, there is a (relatively good) possibility of the FDA approving it with a special label: AUPH discovered that reducing their dosage on certain patients throughout treatment increases renal response. This has been patented until 2037. A label which specifies this guarantees 16 years!! of leading the market.

I'm not saying it's not risky. If it doesn't get approved we're looking at an 80% loss of money. An approval with label puts us at least at $30 and a huge chance of buyout. Rejection is possible, but I don't think it will happen here.

In less than 2 hours we'll start our moon mission, bros.

Take the AUPH pill.

PDUFA deadline is TODAY.

If approved, it will be the best lupus nephritis drug on the market. The only other one is made by GIK, but:
>Oral pill vs IV
>More effective
Who will take IV's for a year, in the corona-climate, when you can just take a nice little pill?

The company has $400m in cash right now, with more than $50m more from their partner (Otsuka) on approval.

Drug has been fast-tracked due to the incredibly good P2 results (p<0.001)

lupus.org estimates up to 1.5 million people with lupus. PG says 400K. 70% of that 400K will be of the SLE form of lupus or 280K. Of those 280K, 40%(PG) or 112K will get LN.

Let's assume a modest market penetration of 15% = 17k patients. With a yearly treatment cost of 70k, we are looking at a (very conservative) 1.2B in revenue per year. This is only in the US.

We are sitting on a 1.91B market cap and 126M shares out. The ratios are incredible.

AUPH has 2027 patent of composition guaranteed for their drug, which means 6 full years of profits. However, there is a (relatively good) possibility of the FDA approving it with a special label: AUPH discovered that reducing their dosage on certain patients throughout treatment increases renal response. This has been patented until 2037. A label which specifies this guarantees 16 years!! of leading the market.

I'm not saying it's not risky. If it doesn't get approved we're looking at an 80% loss of money. An approval with label puts us at least at $30 and a huge chance of buyout. Rejection is possible, but I don't think it will happen here.

The AUPH pill. Take it.